These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 35716998)

  • 21. Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period.
    Bain E; Wilson A; Tooher R; Gates S; Davis LJ; Middleton P
    Cochrane Database Syst Rev; 2014 Feb; (2):CD001689. PubMed ID: 24519568
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the effectiveness and safety of low-molecular weight heparin versus unfractionated heparin anticoagulation after heart valve surgery.
    Bucci C; Geerts WH; Sinclair A; Fremes SE
    Am J Cardiol; 2011 Feb; 107(4):591-4. PubMed ID: 21184996
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Major bleeding in hemodialysis patients using unfractionated or low molecular weight heparin: a single-center study.
    Nadarajah L; Fan S; Forbes S; Ashman N
    Clin Nephrol; 2015 Nov; 84(5):274-9. PubMed ID: 26365216
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
    Holzheimer RG
    Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low molecular weight heparin is associated with better outcomes than unfractionated heparin for thromboprophylaxis in hospitalized COVID-19 patients: a meta-analysis.
    Alsagaff MY; Mulia EPB; Maghfirah I; Azmi Y; Rachmi DA; Yutha A; Andira LH; Semedi BP
    Eur Heart J Qual Care Clin Outcomes; 2022 Nov; 8(8):909-918. PubMed ID: 35921219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incidence of pancreas graft thrombosis using low-molecular-weight heparin.
    Schenker P; Vonend O; Ertas N; Wunsch A; Schaeffer M; Rump LC; Viebahn R
    Clin Transplant; 2009; 23(3):407-14. PubMed ID: 19537302
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low molecular weight heparin for prevention of microvascular occlusion in digital replantation.
    Chen YC; Chi CC; Chan FC; Wen YW
    Cochrane Database Syst Rev; 2013 Jul; (7):CD009894. PubMed ID: 23836382
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of Safety between Different Kinds of Heparins in Patients Receiving Intra-Aortic Balloon Counterpulsation.
    Guan X; Chen M; Li Y; Zhang J; Xu L; Sun H; Zhang D; Wang L; Yang X
    Thorac Cardiovasc Surg; 2021 Sep; 69(6):511-517. PubMed ID: 32998166
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anticoagulation for people with cancer and central venous catheters.
    Kahale LA; Tsolakian IG; Hakoum MB; Matar CF; Barba M; Yosuico VE; Terrenato I; Sperati F; Schünemann H; Akl EA
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006468. PubMed ID: 29856471
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low-Molecular Weight Heparin is Superior to Unfractionated Heparin for Elderly Trauma Patients.
    Gaitanidis A; Breen KA; Christensen MA; Saillant NN; Kaafarani HMA; Velmahos GC; Mendoza AE
    J Surg Res; 2021 Dec; 268():432-439. PubMed ID: 34416415
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low-molecular-weight heparin and unfractionated heparin in prophylaxis against deep vein thrombosis in critically ill patients undergoing major surgery.
    De A; Roy P; Garg VK; Pandey NK
    Blood Coagul Fibrinolysis; 2010 Jan; 21(1):57-61. PubMed ID: 19844176
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Unfractionated Heparin Safety in COVID-19: Incidence and Risks of Bleeding Complications in Japan.
    Sato L; Iwamoto N; Kakumoto Y; Tsuzuki S; Togano T; Ishikane M; Okumura N; Yamada G; Inada M; Suzuki T; Hojo M; Takasaki J; Sasaki R; Kimura A; Teruya K; Okamoto T; Hayakawa K; Hara H; Iseki K; Ohmagari N
    J Atheroscler Thromb; 2024 Aug; 31(8):1179-1193. PubMed ID: 38355124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low-molecular-weight heparin vs unfractionated heparin for perioperative thromboprophylaxis in patients with cancer: a systematic review and meta-analysis.
    Akl EA; Terrenato I; Barba M; Sperati F; Sempos EV; Muti P; Cook DJ; Schünemann HJ
    Arch Intern Med; 2008 Jun; 168(12):1261-9. PubMed ID: 18574082
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE).
    Brieger D; Van de Werf F; Avezum A; Montalescot G; Kennelly BM; Granger CB; Goodman SG; Dabbous OH; Agnelli G;
    Am Heart J; 2007 Jun; 153(6):960-9. PubMed ID: 17540196
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Certoparin-Study Group.
    Kirchmaier CM; Wolf H; Schäfer H; Ehlers B; Breddin HK
    Int Angiol; 1998 Sep; 17(3):135-45. PubMed ID: 9821025
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism.
    Erkens PM; Prins MH
    Cochrane Database Syst Rev; 2010 Sep; (9):CD001100. PubMed ID: 20824828
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inverse relationship of bleeding risk with clot burden during pulmonary embolism treatment with LMW heparin.
    Wang C; Zhai Z; Yang Y; Cheng Z; Ying K; Liang L; Dai H; Huang K; Lu W; Zhang Z; Cheng X; Shen YH; Davidson BL;
    Clin Respir J; 2016 Sep; 10(5):596-605. PubMed ID: 25619125
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of low molecular weight heparin, unfractionated heparin and warfarin for thrombo-embolism prophylaxis in orthopaedic surgery: a meta-analysis of randomised clinical trials.
    Palmer AJ; Koppenhagen K; Kirchhof B; Weber U; Bergemann R
    Haemostasis; 1997; 27(2):75-84. PubMed ID: 9212355
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis.
    Riess H; Koppenhagen K; Tolle A; Kemkes-Matthes B; Gräve M; Patek F; Drexler M; Siemens HJ; Harenberg J; Weidinger G; Brom J; Haas S;
    Thromb Haemost; 2003 Aug; 90(2):252-9. PubMed ID: 12888872
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic dosing of low-molecular-weight heparin may decrease mortality in patients with severe COVID-19 infection.
    Canoglu K; Saylan B
    Ann Saudi Med; 2020; 40(6):462-468. PubMed ID: 33307734
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.